Artificial Pancreas Device System Market Analysis and Key trends
- Get link
- X
- Other Apps
Insulin administration might be difficult for type 1 diabetes (T1D) patients on a daily basis. Insulin pumps, pens, and jet injectors have made diabetes management easier by eliminating the need for uncomfortable insulin delivery devices like needles and syringes. Furthermore, organisations like the Juvenile Diabetes Research Foundation (JDRF) have partnered with industry leaders like Medtronic, Inc., Johnson & Johnson, and Tandem Diabetes Care, Inc. to develop breakthrough insulin and glucose monitoring systems/devices.
An insulin pump,
sensor, transmitter, and receiver are all part of the artificial pancreas
device system (APDS). Medtronic, Inc.'s MiniMed 530G was the first artificial
pancreas device system (APDS) to be approved by the US Food and Drug
Administration.
An insulin
pump coupled to a continuous glucose monitor is referred to as an artificial
pancreas. The monitor is controlled by sophisticated software algorithms
through a receiver. It is used to aid in the regulation of blood sugar levels
in persons with type 1 diabetes. The only enzyme-based hormone insulin that is
now available is delivered by current technologies. Because the body normally
produces and excretes insulin, the use of an artificial pancreas can assist
diabetics reduce their insulin requirements by reducing the amount of the
hormone generated and expelled. In most cases, they are less expensive than
manual methods.
Artificial
Pancreas Device System Market Key Trends
For the
development of innovative artificial
pancreas device systems Market, key market players are focused on
strategic alliances and collaborations. Such collaborations among key companies
may result in the creation of novel devices, propelling the artificial pancreas
device system (APDS) market forward over the forecast period. For example,
Diabeloop SA and ViCentra signed a distribution deal in April 2019 to make the
DBLG1 artificial pancreas system commercially available in several European
countries. Medtronic Plc. and DreaMed Diabetes, an Israeli firm, signed a deal
in 2015 to incorporate DreaMed's patented artificial pancreas technology into Medtronic's
insulin pumps. DreaMed got secret royalties for Medtronic devices that use the
flagship GlucoSitter automated insulin administration system, according to the
deal.
Artificial Pancreas Device System |
- Get link
- X
- Other Apps
Comments
Post a Comment